Adezmapimod: Combination of intensity modulated radiotherapy followed treatment with p38 MAPK activation inhibitor inhibits the proliferation of MCF-7 breast cancer cells

BAY 85-3934: First-in-man / proof of concept study with molidustat – a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia